St Jude Medical announces name change for neuromodulation division

17 December 2008

St Jude Medical, Inc. (NYSE:STJ) has announced that its neuromodulation division, formerly Advanced Neuromodulation Systems, has adopted the St Jude Medical name.

St Jude Medical, which acquired Advanced Neuromodulation Systems in 2005, develops, manufactures and markets implantable neuromodulation products with the goal of improving the quality of life for millions of people who suffer from disabling chronic pain and nervous system disorders.
“The neuromodulation division of St. Jude Medical has a rich history of innovation and excellence that began more than 25 years ago and continues to the present day,” said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. “Our mission is to develop medical technologies and services that put more control into the hands of those who treat neurological and chronic pain patients worldwide. Ultimately, we have helped thousands of chronic pain patients realize that life can indeed get better.”

“St. Jude Medical has consistently demonstrated its commitment to the future of neuromodulation, and the benefits and relief it can offer patients suffering from chronic pain and other neurological disorders,” said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. ”Chronic pain is a growing problem worldwide, with one in five people suffering from this condition.”

While there is a large body of literature on the success of SCS, evidence continues to support its safety and effectiveness as a treatment for severe chronic pain. Published reports in Neurosurgery, Spine, The Journal of the American Medical Association and other publications indicate that SCS is more clinically effective than repeated back surgery and more cost effective. In a comprehensive review of more than 30 published studies, findings confirm the effectiveness of SCS as an early treatment option for failed back surgery syndrome patients.

In the United Kingdom earlier this year, the National Institute for Health and Clinical Excellence (NICE) recommended that spinal cord stimulation be made available to all patients who continue to experience chronic neuropathic pain for at least six months despite trying conventional approaches to pain management. To review the NICE guidance, please visit
St. Jude Medical is developing new technologies to address a growing list of neurological disorders. Clinical studies are currently underway for Parkinson’s disease, essential tremor, migraine headaches and major depressive disorder among others. In addition, St. Jude Medical continues to support educational outreach efforts through such organizations as the National Pain Foundation, American Society of Interventional Pain Physicians, the Neuromodulation Therapy Access Coalition and others.

Bookmark this page

To top